Quantum Biopharma (QNTM) to Release Earnings on Friday

Posted by Defense World Staff on Mar 20th, 2026

Quantum Biopharma (NASDAQ:QNTM – Get Free Report) is anticipated to issue its results before the market opens on Friday, March 27th. Analysts expect the company to announce earnings of ($0.22) per share for the quarter.

Quantum Biopharma Stock Down 1.7%

QNTM stock opened at $2.36 on Friday. The stock has a market cap of $9.02 million, a PE ratio of -0.22 and a beta of 0.32. The firm’s 50-day simple moving average is $4.35 and its 200 day simple moving average is $9.32. Quantum Biopharma has a fifty-two week low of $2.07 and a fifty-two week high of $38.25.

Institutional Trading of Quantum Biopharma

A hedge fund recently bought a new stake in Quantum Biopharma stock. Jane Street Group LLC bought a new stake in Quantum Biopharma Ltd. (NASDAQ:QNTM – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 10,892 shares of the company’s stock, valued at approximately $80,000. Jane Street Group LLC owned approximately 0.29% of Quantum Biopharma as of its most recent SEC filing. Institutional investors own 1.24% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Quantum Biopharma in a research note on Monday, December 29th. Wall Street Zen cut Quantum Biopharma from a “hold” rating to a “sell” rating in a report on Saturday, January 24th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Quantum Biopharma currently has a consensus rating of “Sell”.

View Our Latest Stock Analysis on QNTM

About Quantum Biopharma

(Get Free Report)

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property.